BioSpace News Archive

Optinose, a pharmaceutical company focused on patients treated by ear, nose and throat and allergy specialists, announced the commencement of a proposed underwritten public offering of shares of its common stock.

Precision Optics Corporation, Inc. (OTCQB: PEYE), a leading designer and manufacturer of advanced optical instruments for the medical and defense industries, today announced preliminary revenue for the fourth quarter and fiscal year end 2020, ended June 30, 2020.

Grand River Aseptic Manufacturing, a leading parenteral contract development and manufacturing organization, was recognized in Inc. Magazine’s Inc. 5000 list for the fourth consecutive year.

Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today announced the appointment of Sarah O’Dowd as an independent director to the Protagonist Board of Directors. Ms. O’Dowd brings broad experience in management and corporate governance to Protagonist, including senior level oversight in the biopharmaceutical industry. In connection w

Company Received Over $17.5 Million Net Proceeds from PH94B Upfront License Payment and Public Offering of Common Stock Subsequent to Quarter-end Positive Meeting with the FDA Sets Key Aspects of Pivotal PH94B Phase 3 Study [13-August-2020] SOUTH SAN FRANCISCO, Calif. , Aug. 13, 2020 /PRNewswire/ -- VistaGen Therapeutics, Inc. (Nasdaq: VTGN), a biopharmaceut

Entered into two new collaborations with top tier animal health companies Entered into a fully funded human health collaboration with a top five global pharmaceutical company Started an animal trial for SARS-CoV-2 RBD vaccine candidate in Israel and another animal trial in European is expected to begin soon

9 Meters Biopharma, Inc. today announced that the Executive Management team will participate in the Prepping ahead of Data Conference Call Series hosted by hosted by Srikripa Devarakonda, PhD and Robyn Karnauskas, PhD

ReShape Lifesciences Inc. (OTCQB:RSLS), a global weight-loss solutions leader, today reported financial and operational results for the three months ended June 30, 2020.

UNION therapeutics A/S (“UNION”) today announced the completion of an agreement with TFF Pharmaceuticals, Inc. (“TFF”) to acquire an option to obtain a worldwide exclusive license for the use of their Thin Film Freezing technology in combination with niclosamide to focus on treatments for COVID-19.

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the three months ended June 30, 2020, and provided an update on its corporate activities and product pipeline.